Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
Rivera et al.
, Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer..
, Cancer Discovery, doi:10.1158/2159-8290.CD-20-0941
Retrospective cancer patients, showing adjusted OR 1.03 [0.62-1.73] for HCQ. The study reports the number of HCQ+AZ patients but they do not provide results for HCQ+AZ (only HCQ + any other treatment). Significant confounding by indication
and compassionate use is likely.
risk of death, 2.4% higher, RR 1.02, p = 0.92, treatment 44 of 179 (24.6%), control 59 of 327 (18.0%), adjusted per study, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rivera et al., 22 Jul 2020, retrospective, USA, peer-reviewed, 45 authors.
Abstract: Published OnlineFirst July 22, 2020; DOI: 10.1158/2159-8290.CD-20-0941
Utilization of COVID-19 Treatments and
Clinical Outcomes among Patients with
Cancer: A COVID-19 and Cancer Consortium
(CCC19) Cohort Study
Donna R. Rivera1, Solange Peters2, Orestis A. Panagiotou3, Dimpy P. Shah4, Nicole M. Kuderer5,
Chih-Yuan Hsu6, Samuel M. Rubinstein7, Brendan J. Lee7, Toni K. Choueiri8, Gilberto de Lima Lopes Jr.9,
Petros Grivas10,11, Corrie A. Painter12, Brian I. Rini7, Michael A. Thompson13, Jonathan Arcobello14,
Ziad Bakouny8, Deborah B. Doroshow15,16, Pamela C. Egan17, Dimitrios Farmakiotis18, Leslie A. Fecher19,
Christopher R. Friese20, Matthew D. Galsky15,16, Sanjay Goel21, Shilpa Gupta22, Thorvardur R. Halfdanarson23,
Balazs Halmos21, Jessica E. Hawley24, Ali Raza Khaki10, Christopher A. Lemmon22, Sanjay Mishra25,
Adam J. Olszewski17, Nathan A. Pennell22, Matthew M. Puc26, Sanjay G. Revankar14, Lidia Schapira27,
Andrew Schmidt8, Gary K. Schwartz24, Sumit A. Shah27, Julie T. Wu27, Zhuoer Xie23, Albert C. Yeh10,
Huili Zhu15, Yu Shyr6, Gary H. Lyman11, and Jeremy L. Warner7,28 on behalf of the COVID-19 and
Published OnlineFirst July 22, 2020; DOI: 10.1158/2159-8290.CD-20-0941
Among 2,186 U.S. adults with invasive cancer and laboratory-confirmed SARSCoV-2 infection, we examined the association of COVID-19 treatments with 30-day
all-cause mortality and factors associated with treatment. Logistic regression with multiple adjustments (e.g., comorbidities, cancer status, baseline COVID-19 severity) was performed. Hydroxychloroquine with any other drug was associated with increased mortality versus treatment with any COVID-19
treatment other than hydroxychloroquine or untreated controls; this association was not present with
hydroxychloroquine alone. Remdesivir had numerically reduced mortality versus untreated controls
that did not reach statistical significance. Baseline COVID-19 severity was strongly associated with
receipt of any treatment. Black patients were approximately half as likely to receive remdesivir as
white patients. Although observational studies can be limited by potential unmeasured confounding, our findings add to the emerging understanding of patterns of care for patients with cancer and
COVID-19 and support evaluation of emerging treatments through inclusive prospective controlled
SIGnIfICAnCE: Evaluating the potential role of COVID-19 treatments in patients with cancer in a
large observational study, there was no statistically significant 30-day all-cause mortality benefit with
hydroxychloroquine or high-dose corticosteroids alone or in combination; remdesivir showed potential
benefit. Treatment receipt reﬂects clinical decision-making and suggests disparities in medication
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.